Barclays PLC Grows Position in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA)

Barclays PLC lifted its holdings in shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) by 404.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,341 shares of the company’s stock after purchasing an additional 25,130 shares during the quarter. Barclays PLC owned 0.07% of Verrica Pharmaceuticals worth $45,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Simplify Asset Management Inc. bought a new stake in Verrica Pharmaceuticals during the second quarter valued at approximately $2,041,000. Verition Fund Management LLC purchased a new stake in shares of Verrica Pharmaceuticals during the 3rd quarter valued at $89,000. State Street Corp lifted its holdings in shares of Verrica Pharmaceuticals by 13.5% during the 3rd quarter. State Street Corp now owns 512,821 shares of the company’s stock worth $744,000 after acquiring an additional 61,041 shares during the last quarter. Quest Partners LLC purchased a new position in Verrica Pharmaceuticals in the second quarter worth $50,000. Finally, XTX Topco Ltd bought a new position in Verrica Pharmaceuticals in the third quarter valued at $335,000. Hedge funds and other institutional investors own 42.45% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on VRCA shares. Royal Bank of Canada lowered Verrica Pharmaceuticals from an “outperform” rating to a “sector perform” rating and dropped their price target for the stock from $11.00 to $2.00 in a research note on Tuesday, November 5th. TD Cowen dropped their target price on Verrica Pharmaceuticals from $15.00 to $10.00 and set a “buy” rating for the company in a research report on Monday, October 21st. HC Wainwright cut shares of Verrica Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Wednesday, November 6th. Brookline Capital Management restated a “hold” rating on shares of Verrica Pharmaceuticals in a report on Wednesday, October 2nd. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Verrica Pharmaceuticals in a research note on Friday, December 20th. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $9.50.

Verrica Pharmaceuticals Stock Down 6.7 %

Shares of NASDAQ:VRCA opened at $0.70 on Friday. The firm has a market capitalization of $31.91 million, a P/E ratio of -0.38 and a beta of 1.49. The company has a debt-to-equity ratio of 29.58, a quick ratio of 1.22 and a current ratio of 1.34. The stock has a 50 day moving average price of $0.88 and a 200-day moving average price of $2.85. Verrica Pharmaceuticals Inc. has a 52-week low of $0.61 and a 52-week high of $11.41.

Verrica Pharmaceuticals (NASDAQ:VRCA) last posted its quarterly earnings data on Monday, November 4th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.12). The business had revenue of ($1.78) million for the quarter, compared to the consensus estimate of $7.53 million. Verrica Pharmaceuticals had a negative return on equity of 591.84% and a negative net margin of 625.06%. As a group, equities research analysts anticipate that Verrica Pharmaceuticals Inc. will post -1.42 EPS for the current fiscal year.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.